Search Results - "Appenfeller, Allison"

“Waitlist mortality” is high for myeloma patients with limited access to BCMA therapy by Ahmed, Nausheen, Wesson, William, Mushtaq, Muhammad Umair, Bansal, Rajat, AbdelHakim, Haitham, Bromert, Sarah, Appenfeller, Allison, Ghazal, Batool Abu, Singh, Anurag, Abhyankar, Sunil, Ganguly, Siddhartha, McGuirk, Joseph, Abdallah, Al-Ola, Shune, Leyla

“…Background The first-in-class approved BCMA CAR-T therapy was idecabtagene vicleucel (ide-cel), approved in March 2021, for RRMM patients who progressed after…”
Get full text

Safety and Cost Effectiveness of Chimeric Antigen Receptor T Cell Therapy in the Outpatient Setting by Shahzad, Moazzam, Faisal, Muhammad Salman, Shippey, Ernie, Hussain, Ali, Divine, Clint, Mahmoudjafari, Zahra, Appenfeller, Allison, Mushtaq, Muhammad Umair, Shune, Leyla, McGuirk, Joseph P., Ahmed, Nausheen

“…Introduction Since the commercial approval of chimeric antigen receptor T cell (CAR-T) therapies, administration and toxicity monitoring have largely been in…”
Get full text

Is chimeric antigen receptor T cell (CART) a destination procedure? Lower socioeconomic class who live farther from center have less access to CART by Ahmed, Nausheen, Shippey, Ernie, Kus, Crissy, Appenfeller, Allison, Hoffmann, Marc Steven, Tun, Aung M., Ganguly, Siddhartha, Shune, Leyla, Devine, Clint, Bansal, Rajat, Abhyankar, Sunil H., Mushtaq, Muhammad Umair, McGuirk, Joseph

“…Abstract only e18562 Background: Axicabtagene ciloleucel and tisagenlecleucel are commercially available CD19 chimeric antigen receptor T-cell (CART) therapies…”
Get full text

Chimeric Antigen Receptor T-Cell (CAR-T) Access Among Rural and Health Professional Shortage Area (HPSA) Populations in the Midwest by Tabak, Carine, Rashid, Aliya, Pepper, Sam, Wesson, William, Abdallah, Al-Ola, Lutfi, Forat, Mushtaq, Muhammad Umair, Hoffmann, Marc, Bromert, Sarah, Appenfeller, Allison, Winters, Erin, Lin, Tara L, Baranda, Joaquina Celebre, McGuirk, Joseph P, Mudaranthakam, Dinesh Pal, Ahmed, Nausheen

“…Chimeric antigen receptor T-cell (CAR-T) therapy has improved outcomes in non-Hodgkin lymphoma (NHL) and multiple myeloma (MM). However, only a fraction of…”
Get full text

Single Institution Experience with Myeloma Patients for Commercially Approved BCMA Chimeric Antigen Receptor T Cell Therapy (CART) Idecabtagene-Vicleucel (Ide-cel) by Ahmed, Nausheen, Abdallah, Al-Ola, Bromert, Sarah, Appenfeller, Allison, Abdelhakim, Haitham, Bansal, Rajat, Mahmoudjafari, Zahra, Mushtaq, Muhammad Umair, Singh, Anurag K, Abhyankar, Sunil, Ganguly, Siddhartha, McGuirk, Joseph P., Shune, Leyla

Get full text

297 - Single Institution Experience with Myeloma Patients for Commercially Approved BCMA Chimeric Antigen Receptor T Cell Therapy (CART) Idecabtagene-Vicleucel (Ide-cel) by Ahmed, Nausheen, Abdallah, Al-Ola, Bromert, Sarah, Appenfeller, Allison, Abdelhakim, Haitham, Bansal, Rajat, Mahmoudjafari, Zahra, Mushtaq, Muhammad Umair, Singh, Anurag K, Abhyankar, Sunil, Ganguly, Siddhartha, McGuirk, Joseph P., Shune, Leyla

Get full text

Code BMT: A System for Seamless Patient Admission in an Outpatient BMT Program by Appenfeller, Allison, Botterbush, Julie, Rimkus, Chris, Fesler, Mark

Get full text

126 - Code BMT: A System for Seamless Patient Admission in an Outpatient BMT Program by Appenfeller, Allison, Botterbush, Julie, Rimkus, Chris, Fesler, Mark

Get full text

Successful Anti-CD 19 CAR-T Cell Therapy in Jehovah Witness Patient with Relapsed Refractory B-ALL by Leal, Jordan, Rodriguez, Liza, Kus, Crissy, Appenfeller, Allison, Ganguly, Siddhartha, McGuirk, Joseph P., Abhyankar, Sunil, Singh, Anurag, Lin, Tara, Shune, Leyla

“…Jehovah Witness is a minority Christian denomination whose members do not accept blood products. The population of Jehovah witness is approximately 1 million…”
Get full text